Page 156 - 南京医科大学自然版

第44卷第12期
·1770 · 南 京 医 科 大 学 学 报 2024年12月

杂志，2024，34（6）：907-911 ［30］GRIFFITHS C D，BILAWCHUK L M，MCDONOUGH J
［17］KE Z L，DILLARD R S，CHIRKOVA T，et al. The mor⁃ E，et al. IGF1R is an entry receptor for respiratory syncy⁃
phology and assembly of respiratory syncytial virus re⁃ tial virus［J］. Nature，2020，583（7817）：615-619
vealed by cryo⁃electron tomography［J］. Viruses，2018，10 ［31］ZHANG L W，WAN Y，MA L，et al. Inhibition of NF⁃κB/
（8）：446 IL⁃33/ST2 axis ameliorates acute bronchiolitis induced by
［18］SHANG Z F，TAN S G，MA D L. Respiratory syncytial respiratory syncytial virus［J］. J Immunol Res，2021，
virus：from pathogenesis to potential therapeutic strate⁃ 2021：6625551
gies［J］. Int J Biol Sci，2021，17（14）：4073-4091 ［32］TAHAMTAN A，SAMADIZADEH S，RASTEGAR M，et
［19］CANTÚ⁃FLORES K，RIVERA⁃ALFARO G，MUÑOZ⁃ES⁃ al. Respiratory syncytial virus infection：Why does dis⁃
CALANTE J C，et al. Global distribution of respiratory ease severity vary among individuals?［J］. Expert Rev
syncytial virus A and B infections：a systematic review［J］. Respir Med，2020，14（4）：415-423
Pathog Glob Health，2022，116（7）：398-409 ［33］OZCAN A，LASKOWSKI E，SAHA I，et al. Febrile infants
［20］范如艳. 儿童呼吸道合胞病毒分子流行病学及其致炎 without respiratory symptoms or sick contacts：Are chest
症反应机制研究［D］. 衡阳：南华大学，2016 radiographs or RSV/influenza testing indicated?［J］. BMC
［21］BEUGELING M，DE ZEE J，WOERDENBAG H J，et al. Infect Dis，2021，21（1）：862
Respiratory syncytial virus subunit vaccines based on the ［34］吴 铭，张 华，武 怡，等. 呼吸道合胞病毒感染对肺
viral envelope glycoproteins intended for pregnant women 组织 GRK2 的影响及其与哮喘的关系［J］. 南京医科大
and the elderly［J］. Expert Rev Vaccines，2019，18（9）： 学学报（自然科学版），2014，34（11）：1463-1468
935-950 ［35］BALAS W M， SLIWCZYNSKI A，OLSZEWSKI P，et al.
［22］MCLELLAN J S，CHEN M，LEUNG S，et al. Structure of Comparative analysis of symptomatology in hospitalized
RSV fusion glycoprotein trimer bound to a prefusion⁃spe⁃ children with RSV，COVID⁃19，and influenza infections［J］.
cific neutralizing antibody［J］. Science，2013，340（6136）： Med Sci Monit，2023，29：e941229
1113-1117 ［36］CHECCHIA P. Identification and management of severe
［23］GILBERT B E，PATEL N，LU H X，et al. Respiratory syn⁃ respiratory syncytial virus［J］. Am J Health Syst Pharm，
cytial virus fusion nanoparticle vaccine immune respon ⁃ 2008，65（23 Suppl 8）：S7⁃S12
ses target multiple neutralizing epitopes that contribute to ［37］PIERANGELI A，NENNA R，FRACELLA M，et al. Genetic
protection against wild⁃type and palivizumab⁃resistant mu⁃ diversity and its impact on disease severity in respiratory
tant virus challenge［J］. Vaccine，2018，36（52）：8069-8078 syncytial virus subtype⁃A and⁃B bronchiolitis before and
［24］LUNA M S，MANZONI P，PAES B，et al. Expert consen⁃ after pandemic restrictions in Rome［J］. J Infect，2023，87
sus on palivizumab use for respiratory syncytial virus in （4）：305-314
developed countries［J］. Paediatr Respir Rev，2020，33： ［38］POLACK F P，ALVAREZ⁃PAGGI D，LIBSTER R，et al.
35-44 Fatal enhanced respiratory syncytial virus disease in tod⁃
［25］KEAM S J. Nirsevimab：first approval［J］. Drugs，2023，83 dlers［J］. Sci Transl Med，2021，13（616）：eabj7843
（2）：181-187 ［39］CHEN F J，PARK H R，JI H J，et al. Gamma irradiation⁃
［26］ZHU Q，MCLELLAN J S，KALLEWAARD N L，et al. A inactivated respiratory syncytial virus vaccine provides
highly potent extended half ⁃ life antibody as a potential protection but exacerbates pulmonary inflammation by
RSV vaccine surrogate for all infants［J］. Sci Transl Med， switching from prefusion to postfusion F protein［J］.
2017，9（388）：eaaj1928 Microbiol Spectr，2023，11（4）：e0135823
［27］HALAJIAN E A，LEBLANC E V，GEE K，et al. Activa⁃ ［40］MUKHAMEDOVA M，WRAPP D，SHEN C H，et al. Vac⁃
tion of TLR4 by viral glycoproteins：a double ⁃ edged cination with prefusion ⁃ stabilized respiratory syncytial
sword?［J］. Front Microbiol，2022，13：1007081 virus fusion protein induces genetically and antigenically
［28］FENG Z H，XU L L，XIE Z D. Receptors for respiratory diverse antibody responses［J］. Immunity，2021，54（4）：
syncytial virus infection and host factors regulating the 769-780
life cycle of respiratory syncytial virus［J］. Front Cell Infect ［41］MAZUR N I，TERSTAPPEN J，BARAL R，et al. Respira⁃
Microbiol，2022，12：858629 tory syncytial virus prevention within reach：the vaccine
［29］CURRIER M G，LEE S J，STOBART C C，et al. EGFR and monoclonal antibody landscape［J］. Lancet Infect
interacts with the fusion protein of respiratory syncytial Dis，2023，23（1）：2-21
virus strain 2 ⁃ 20 and mediates infection and mucin ［42］WRIGHT P F，KARRON R A，BELSHE R B，et al. The
expression［J］. PLoS Pathog，2016，12（5）：e1005622 absence of enhanced disease with wild type respiratory